Jonathan Robbins


Jonathan joined Foresite Capital in 2023 as a member of the investment team focusing on evaluating investment opportunities. Jonathan additionally supports company ideation and incubation through Foresite Labs.

Jon is a physician scientist who joined Foresite Capital from Merck Research Laboratories, where he was an Executive Director (Distinguished Scientist) and Therapeutic Area Head for Immunology in Translational Medicine. At Merck, Jon was responsible for the oversight of early clinical development from first in human through proof of concept, as well as the evaluation of external assets in the Immunology space. Jonathan additionally led the strategy and clinical execution for multiple programs spanning neuroscience, general medicine, infectious diseases and vaccines. Previously, Jon was on faculty at Harvard Medical School and Brigham and Women’s Hospital.

Jon received his B.A. in Biology from the University of Pennsylvania, his M.D. from Cornell University and his Ph.D. from the Rockefeller University. He completed training in Internal Medicine at Brigham and Women’s Hospital, and his fellowship in Infectious Diseases at the combined Brigham and Women’s/Massachusetts General Hospital program.


  • B.A. from University of Pennsylvania, M.D. from Cornell University, Ph.D. from Rockefeller University. Completed residency and fellowship training at Brigham and Women’s Hospital and Massachusetts General Hospital
  • Served as Therapeutic Area Head for Immunology in Translational Medicine at Merck, and led clinical stage programs across multiple therapeutic areas